Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zanubrutinib by BeiGene for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...
Zanubrutinib by BeiGene for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
Zanubrutinib by BeiGene for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...
Zanubrutinib by BeiGene for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Zanubrutinib by BeiGene for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zanubrutinib is under clinical development by BeiGene and currently in Phase III for Refractory Chronic Lymphocytic Leukemia (CLL). According to...